(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Posts claimed Barbra Streisand was battling glioblastoma, an aggressive form of brain cancer, without citing any evidence.

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX). Published in Cell Reports, the study found ...

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, ...

Kyntra Bio, Inc. (NASDAQ:KYNB) Q4 2025 Earnings Call Transcript March 16, 2026 Kyntra Bio, Inc. beats earnings expectations. Reported EPS is $-3.61, expectations were $-3.885. Operator: Thank you for ...

A 1951 CIA report on parasites and tumors spread online in March 2026 — but it was declassified years ago and does not reveal a cancer cure.

SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the fourth quarter and full year 2025 and provided an update on the company’s recent ...

Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, ...

Patients with myelodysplastic syndromes (MDS) exhibit diverse disease trajectories necessitating different clinical approaches ranging from watch-and-wait strategies to hematopoietic stem cell ...

BUFFALO GROVE, Ill., Dec. 19, 2025 /PRNewswire/ -- Tolmar, Inc. (Tolmar) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Rubraca® (rucaparib), ...

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...